TOXO-MOX
Dry Syrup
COMPOSITION:
Each 5 ml reconstituted suspension contains
Amoxycillin Trihydrate IP Eq. to Amoxycillin 200 mg
Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 28.5 mg
Excipients Q.S
DESCRIPTION
TOXO-MOX Dry Syrup (Amoxycillin trihydrate and Potassium clavulanate Oral Suspension IP) is an orally administered formulation comprised of the broad-spectrum antibiotic Amoxycillin trihydrate and the p-lactamase inhibitor, Potassium clavulanate (the potassium salt of clavulanic acid).
Amoxycillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative, aerobic and anaerobic microorganisms. It does not resist destruction by B-lactamases: therefore, it is not effective against B-lactamase producing bacteria. Chemically, it is D(-)-a-amino-p-hydroxybenzy penicillin trihydrate.
Clavulanic acid, an inhibitor of B-lactamase enzymes, is produced by the fermentation of Streptomyces clavuligerus. Clavulanic acid by itself has only weak antibacterial activity. Chemically, Clavulanate potassium is potassium z-(3R,5R)-2-B-hydroxyethylidene clavam-3-carboxylate.
Amoxycillin is bactericidal in action and acts through the inhibition of biosynthesis of cell wall mucopeptide susceptible organisms.
The action of clavulanic acid extends the antimicrobial spectrum of amoxycillin to include organisms resistant to amoxycillin and other B-lactam antibiotics.
CONTRAINDICATIONS
The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.
WARNINGS
Safety of use in pregnant or breeding animals has not been determined.
VETERINARY
FOR USE IN DOGS AND CATS ONLY NOT FOR HUMAN USE
FOR ANIMAL TREATMENT ONLY
ADVERSE DRUG REACTIONS
TOXO-MOX Dry Syrup contains semisynthetic penicillin (amoxycillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.
PRESENTATION: 30ml Bottle with Sterile Water
Store below 25°C,
TOXO-MOX Dry Syrup is stable in the presence of gastric acid and Is not significantly influenced by gastric or intestinal contents. The components are rapidly absorbed resulting in amoxycillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.
Amoxycillin and clavulanic acid diffuse readily into most body tissues and fluids with the exception of brain and spinal fluid, which amoxycillin penetrates adequately when meninges are intlamed. Most of the amoxycilin is excreted unchanged in the urine. Clavulanic acid's penetration into spinal fluid is unknown at this time. Approximately 15% of the administered dose of clavulanic acid is excreted in the unne within the first 6 hours TOXO-MOX combines the distinctive properties of a broad-spectrum antibiotic and a B-lactamase inhibitor to effectively extend the antibacterial spectrum of amoxycillin to include B-lactamase producing as well as non-B-lactamase producing aerobic and anaerobic organisms.
MICROBIOLOGY
Amoxycillin/Clavulanate has been shown to have a wide range of activity which includes B-lactamase producing strains of both gram-positive and gram-negative aerobes, facultative anaerobes and obligate anaerobes. Many strains of the following organisms including B-lactamase producing strains, isolated from veterinary sources, were found to be susceptible to Amoxycillin/Clavulanate in vitro but the clinical significance of this activity has not been demonstrated for some of these organisms in animals
Aerobic bacteria, including Staphylococcus aureus, B-lactamase producing Staphylococcus aureus (penicillin resistant). Staphylococcus species • Staphylococcus epidermidis, Staphylococcus intermedius, Streptococcus faecalis, Streptococcus species, Corynebacterium pyogenes. Corynebacterium species. Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Eschenchia coli. Proteus mirabilis, Proteus species, Enterobacter species, Kebsiella pneumoniae,Salmonella dublin, Saimonella typhimurium,Pasteurella multocida, Pasteurella laemolytica, Pasteurella species
Studies have demonstrated those both aerobic and anaerobic floras are isolated from gingival cultures of dogs with clinical evidence of periodontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to Amoxycillin/Clavulanic acid during antimicrobial susceptibility testing.
INDICATIONS AND USAGE
TOXO-MOX Dry Syrup is indicated in the treatment of:
Dogs
Skin and soft tissue infections such as wounds, abscesses. superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: B-lactamase producing Staphylococcus aureus, non-B-lactamase producing Staphylococcus aureus, Staphylococcus spp.. Streptococcus spp., and E. col
Peridontal infections due to susceptible strains of aerobic and anaerobic bacteria. TOXO-MOX Dry Syrup has been shown to be clinically effective for treating cases of canine periodontal disease
Cats
Skin and soft tissue infections such as wounds, abscesses, and cellultis/dermatitis due to susceptible strains of the following organisms: B-lactamase producing Staphylococcus aureus, non-B-lactamase producing Staphylococcus aureus, Staphylococcus spp.. Streptococcus spp., E. coli, Pasteurella multocida and Pasteurella spp
Urinary tract infections (cystitis) due to susceptible strains of E.coli
Therapy may be initiated with TOXO-MOX Dry Syrup prior to obtaining results from bacteriological and susceptibility studies
A culture should be obtained prior to treatment to determine susceptibility of the organisms to TOXO-MOX Dry Syrup
Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated
DOSAGE AND ADMINISTRATION
Dogs and Cats: The recommended dosage is 12.5 mg/kg (1 ml /3 kg) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated,
Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days Reconstitution Instructions - Oral Suspension
Slowly add Stenie water up to the ring mark on the bottie. Shake vigorously. Adjust the volume upto the ring mark by adding more water, if necessary. This makes 30 ml suspension. Use the reconstituted suspension within 4 days after reconstitution. Each mL of suspension will contain 40 mg of amoxycillin
Indications:
- Respiratory Tract Infections
- Enteritis/Gastro-intestinal infections
- Dental Infection
Presentation:
30 ml Bottle with Sterile water
